Abstract
The high quality adjusted case series by Saratzis et al. 1 puts another strong counter argument to the paclitaxel increases mortality debate started by the meta-analysis from Katsanos et al. in 2018. 2 The reaction to that meta-analysis was unprecedented in recent times, halting international practice despite widespread adoption of the technology and derailing randomised trials.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Journal | European Journal of Vascular and Endovascular Surgery |
| Early online date | 4 Apr 2020 |
| DOIs |
|
| Publication status | E-pub ahead of print - 4 Apr 2020 |
Fingerprint
Dive into the research topics of 'Paclitaxel and Mortality: Where Are We now?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver